Currency In USD
| Previous Close | 13.39 |
| Open | 13.06 |
| Day High | 13.16 |
| Day Low | 12.6 |
| 52-Week High | 15.35 |
| 52-Week Low | 6.62 |
| Volume | 162,418.26 |
| Average Volume | 1.03M |
| Market Cap | 1.17B |
| PE | -8.53 |
| EPS | -1.48 |
| Moving Average 50 Days | 10.57 |
| Moving Average 200 Days | 8.79 |
| Change | -0.77 |
MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology
GlobeNewswire Inc.
Nov 10, 2025 12:00 PM GMT
LONDON and NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced a broad strategic collaboration in the area of ophthalmology with Eli Li
MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress
GlobeNewswire Inc.
Oct 07, 2025 12:00 PM GMT
Multiple Posters Highlight the Breadth of Company’s Novel Genetic Medicine and Cell Therapy PlatformsLONDON and NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medici
MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting
GlobeNewswire Inc.
May 13, 2025 8:30 PM GMT
Multiple Poster Presentations Highlight the Depth and Novelty of MeiraGTx’s Technology Platforms for Gene and Cell TherapyLONDON and NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical